ルイジアナ州における潰瘍性大腸炎の臨床試験
ルイジアナ州内の拠点で、潰瘍性大腸炎に関する15件の研究が参加者を募集しています。
ルイジアナ州内の都市
公式研究テキスト（英語）
Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
- Gastro Group and Endocenter: Mandeville, la /ID# 284186, Mandeville
- Metropolitan Gastroenterology Associates - Metairie /ID# 283922, Metairie
- Willis-Knighton Medical Center /ID# 280572, Shreveport
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/10/02更新 · NCT07697456A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
- Baton Rouge General Medical Center - Bluebonnet Campus, Baton Rouge
- Combined Gastro LLC, Lafayette
- GI Alliance, Metairie
被験者募集中第4相
18歳〜80歳 · 全性別 · 2026/09/30更新 · NCT06581328A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
- Clinical Trials Management, LLC, Metairie
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/09/30更新 · NCT06598943A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
- Site 035, Marrero
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/09/29更新 · NCT07012395A Trial to Investigate PALI-2108 Versus Placebo in Participants With Moderately to Severely Active Ulcerative Colitis
- Site US-008, Baton Rouge
- Site US-011, Mandeville
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/09/29更新 · NCT07845487A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)
- Tulane University School of Medicine-Gastroenterology and Hepatology ( Site 1073), New Orleans
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/09/28更新 · NCT07463183A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
- Delta Research Partners, LLC, West Monroe
被験者募集中第3相
12歳以上 · 全性別 · 2026/09/25更新 · NCT07196748Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
- Care Access - New Iberia, New Iberia
- Louisiana Research Center, Shreveport
被験者募集中第3相
18歳〜70歳 · 全性別 · 2026/09/24更新 · NCT06937086LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
- GI Alliance - Gastro Group and Endocenter - Mandeville, Mandeville
被験者募集中第2相
18歳〜80歳 · 全性別 · 2026/09/22更新 · NCT07415044A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)
- GI Alliance, Metairie
- Tulane University, New Orleans
被験者募集中第4相
18歳〜65歳 · 全性別 · 2026/09/21更新 · NCT06095128A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
- GI Alliance - Baton Rouge - Site Number: 8400129, Baton Rouge
- Texas Digestive Disease Consultants, PLLC d/b/a GI Alliance - Mandeville - Site Number: 8400128, Mandeville
- Delta Research Partners - Site Number: 8400087, Monroe
被験者募集中第3相
16歳〜80歳 · 全性別 · 2026/09/15更新 · NCT07185009A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
- Gastroenterology Clinic of Acadiana, Lafayette
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/28更新 · NCT07577856An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
- GI Alliance - Baton Rouge - Site Number: 8400129, Baton Rouge
- Tandem Intermediate, LLC - Houma -Site Number: 8400034, Houma
- GastroGroup - Site Number: 8400128, Mandeville
- 他4件
被験者募集中第3相
16歳〜80歳 · 全性別 · 2026/08/20更新 · NCT07184996A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
- Mirador Therapeutics Selected Site, Lafayette
- Mirador Therapeutics Selected Site, Marrero
- Mirador Therapeutics Selected Site, Shreveport
被験者募集中第2相
18歳〜80歳 · 全性別 · 2026/03/12更新 · NCT07113522Study of Efficacy and Adherence to Subcutaneous vs. Intravenous Vedolizumab in Patients With Inflammatory Bowel Disease Using a Novel Remote MONITORing Intervention
- Tulane University, New Orleans
被験者募集中観察研究
18歳以上 · 全性別 · 2025/05/08更新 · NCT06750731ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。